Skip to main content
. 2020 Dec 11;4(24):6157–6168. doi: 10.1182/bloodadvances.2020003036

Table 4.

Univariable prognostic factor analyses for post-CI outcomes (log rank; n=30/39)

Variable CAR T cells alloHCT
P HR Lower CL Upper CL P HR Lower CL Upper CL
OS
 Diagnosis (DLBCL vs other) .59 0.66 0.15 2.97 .0062 0.31 0.14 0.72
 PIF (vs relapse) .37 1.88 0.47 7.55 .036 2.92 1.08 7.94
 Prior lines (>3 vs 2-3) .62 1.02 0.75 1.29 .019 2.91 1.19 7.09
 Prior autoHCT (yes vs no) .17 0.30 0.05 1.71 .44 0.73 0.33 1.61
 Bridging (yes vs no) .029 4.5 1.16 17.4
 Time from indication to CI (> vs < median) .22 2.31 0.61 8.81 .50 1.32 0.60 2.88
 HCT comorbidity index (>0 vs 0) .72 0.76 0.17 3.39 .62 0.82 0.37 1.80
 sIPI (HI/H vs L/LI) .45 1.68 0.44 6.47 .43 1.40 0.65 3.61
 Bulk >10 cm (yes vs no) .0008 23.7 3.73 151
 ZUMA-1 ineligible (yes vs no) .58 1.46 0.39 5.55 .19 1.75 0.76 4.05
 Disease status at conditioning (PD vs CR/PR/SD) .26 2.35 0.54 10.3 .57 1.37 0.46 4.04
 LDH (> normal vs normal) .022 5.18 1.27 21.2 .67 0.84 0.36 1.92
 Calendar year of HCT (<2014 vs ≥2014) .71 0.81 0.39 1.90
 Donor (related vs unrelated) .099 2.08 0.87 4.98
PFS
 Diagnosis (DLBCL vs other) .55 0.70 0.22 2.24 .014 0.37 0.17 0.81
 PIF (vs relapse) .26 1.84 0.64 5.25 .0078 3.59 1.40 9.22
 Prior lines (>3 vs 2-3) .57 1.34 0.50 3.59 .023 2.63 1.14 6.01
 Prior autoHCT (yes vs no) .95 1.05 0.29 3.80 .57 0.81 0.39 1.69
 Bridging (yes vs no) .24 1.84 0.67 5.11
 Time from indication to CI (> vs < median) .26 1.78 0.65 4.85 .88 0.95 0.45 1.97
 HCT comorbidity index (>0 vs 0) .56 0.74 0.27 2.04 .73 1.14 0.54 2.40
 sIPI (HI/H vs L/LI) .53 1.37 0.51 3.72 .56 1.25 0.59 2.64
 Bulk >10 cm (yes vs no) .077 3.50 0.88 14.0
 ZUMA-1 ineligible (yes vs no) .67 0.81 0.44 1.18 .14 1.82 0.83 4.00
 Disease status at conditioning (PD vs CR/PR/SD) .064 2.68 0.95 7.60 .31 1.72 0.60 4.95
 LDH at conditioning (> normal vs normal) .012 3.68 1.34 10.1 .49 0.76 0.35 1.66
 Donor (related vs unrelated) .086 2.03 0.91 4.53

Bold font indicates significance.

.